BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 369 filers reported holding BIO-TECHNE CORP in Q4 2019. The put-call ratio across all filers is 0.69 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $223,000 | -9.3% | 515 | +8.2% | 0.08% | -11.5% |
| Q4 2021 | $246,000 | +6.5% | 476 | 0.0% | 0.09% | -6.5% |
| Q3 2021 | $231,000 | -4.9% | 476 | -11.9% | 0.09% | -9.7% |
| Q2 2021 | $243,000 | +18.0% | 540 | 0.0% | 0.10% | +3.0% |
| Q1 2021 | $206,000 | +329.2% | 540 | +115.1% | 0.10% | +185.7% |
| Q1 2020 | $48,000 | +108.7% | 251 | +139.0% | 0.04% | +105.9% |
| Q4 2019 | $23,000 | – | 105 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ROWLANDMILLER & PARTNERS.ADV | 47,975 | $3,701,751 | 0.85% |
| Diversified Trust Co | 13,882 | $1,071,135 | 0.04% |
| Czech National Bank | 27,698 | $2,137,178 | 0.03% |
| FULTON BANK, N.A. | 5,444 | $420,058 | 0.02% |
| DnB Asset Management AS | 27,637 | $2,132,471 | 0.01% |
| Versant Capital Management, Inc | 36 | $2,778 | 0.00% |
| MASSMUTUAL TRUST CO FSB/ADV | 371 | $28,626 | 0.00% |
| Bartlett & Co. LLC | 172 | $13 | 0.00% |